GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Cannabidiol Oral Solution in Lennox-Gastaut Syndrome

World News: . []

-First dose-rangingstudy comparingpharmaceutical formulation ofcannabidiol to placebo as add-on therapy inLennox-Gastaut syndrome a rare severe and difficult to treat form of childhood-onset epilepsy - -Both doses significantly r educed ...

More news and information about GW Pharmaceuticals plc

Published By:

Thomson Reuters: 22:27 GMT Wednesday 16th May 2018

Published: .

Search for other references to "pharmaceuticals" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us